Contineum Therapeutics, Inc. Class A Common Stock (CTNM) scores 21 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0. Quantitative score: 39/100. Qualitative score: 20/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.